2730 Sidney Street, Ste. 300
Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics' lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.
Leadership: Jonathan Steckbeck (CEO & Founder)
32 articles about Peptilogics
Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients With Periprosthetic Joint Infection (PJI)
Peptilogics, a clinical-stage biotechnology company, today announced top-line interim data of PLG0206 in PJI patients from their ongoing Phase 1b trial.
Peptilogics Completes Phase 1b Trial Enrollment & Will Present Interim Top-line Safety & Tolerability Data of PLG0206 in Patients Undergoing DAIR for the Treatment of Periprosthetic Joint Infection After a Total Knee Arthroplasty at ECCMID 2023
Peptilogics, a clinical stage biotechnology company, has completed the enrollment of a Phase 1b trial for PLG0206 in patients undergoing Debridement, Antibiotics, and Implant Retention for treatment of a Periprosthetic Joint Infection occurring after Total Knee Arthroplasty.
Peptilogics Hosting Panel Discussion with Leading Industry Experts on the High Unmet Medical Need and Opportunity in Periprosthetic Joint Infections (PJI)
Peptilogics announced that it will host a virtual panel discussion with leading industry experts on the high unmet medical need, economic burden, and opportunity in periprosthetic joint infections on Monday, February 27, 2023 at 11 AM ET.
Peptilogics to Present Data at IDWeek 2022 on PLG0206, an Engineered Antimicrobial Peptide Targeting Bacteria Causing Periprosthetic Joint Infection
Peptilogics is presenting two posters featuring preclinical data from its antimicrobial peptide, PLG0206, at ID Week 2022.
Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206
Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, presented preclinical data from its peptide, PLG0206, at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance.
EpiAxis Therapeutics & Peptilogics Enter Strategic Drug Discovery Partnership
EpiAxis Therapeutics and Peptilogics announced today that they have entered a collaboration to leverage AI for drug discovery to inhibit epigenetic oncology targets, aiming to reprogram cancer cells and drive immune reinvigoration.
This week’s Movers & Shakers include Scribe, Appia Bio, Chimerix and KemPharm, all announcing new VP roles. Companies also plan for the future with the implementation of a succession plan.
Peptilogics Strengthens Leadership Team with Executive Appointments
Peptilogics today announced two executive appointments to strengthen and expand its leadership team.
Peptilogics to Participate in Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting in Pittsburgh
Peptilogics will participate in the Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting taking place in Pittsburgh August 5-6.
Peptilogics Receives FDA Fast Track Designation for PLG0206, an Investigational Peptide Therapeutic in Development for the Treatment of Periprosthetic Joint Infection
Peptilogics, a biotech company engineering peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s lead drug candidate, PLG0206.
Orion Biotechnology and Peptilogics Enter Strategic Research Collaboration to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target
Orion Biotechnology Canada Ltd and Peptilogics, announced today that they have entered a research and development collaboration to leverage AI for drug discovery against an undrugged GPCR target.
Peptilogics to Present Data Highlighting Designed Antimicrobial Peptide for the Treatment of Periprosthetic Joint Infection (PJI) at ECCMID 2022
Peptilogics will present one poster and an oral presentation at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
Peptilogics’ Presentations at American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting Highlight Peptide Therapeutic PLG0206 for the Treatment of Periprosthetic Joint Infection (PJI)
Peptilogics will present three papers at the American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting in Chicago March 24.
BioSpace Movers & Shakers, Jan. 28
1/28/2022Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Peptilogics Promotes Nicholas Nystrom, Ph.D., to Chief Technology Officer
Peptilogics, a biotech company that designs peptide therapeutics, today announced that it has promoted Nicholas Nystrom, Ph.D., formerly SVP and Head of Computation and Data, to Chief Technology Officer.
Peptilogics Receives Award from the Cystic Fibrosis Foundation to Investigate PLG0301 and PLG0206 as Potential Dual-Acting Treatments for Lung Infections Associated with Cystic Fibrosis
Peptilogics today announced that the company received an award from the Cystic Fibrosis Foundation.
Peptilogics Announces Two Peer-Reviewed Publications on Designed Peptide Therapeutic PLG0206 for Periprosthetic Joint Infection
Peptilogics today announced two studies on its lead designed peptide therapeutic, PLG0206, an investigational drug, have been published in peer-reviewed journals Antimicrobial Agents and Chemotherapy (AAC) and Microbiology Spectrum.
Peptilogics Presents Positive First-in-Human Phase 1 Data for its Lead Engineered Antibacterial Peptide, PLG0206, at IDWeek 2021
Peptilogics today presented Phase 1 safety and tolerability data on PLG0206, a unique engineered antibacterial peptide being developed for the treatment of prosthetic joint infection (PJI).
Peptilogics to Present First-in-Human Phase 1 Clinical Data of PLG0206 at IDWeek 2021
Peptilogics will present first-in-human Phase 1 data on its lead investigational therapy PLG0206
BioSpace Movers & Shakers, July 30, 2021
7/30/2021Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers.